Combination of Baxter and Gambro enable Baxter to better serve innovative renal products and therapies

Baxter International Inc. (NYSE: BAX) today announced that the company has successfully completed the acquisition of Gambro AB, a privately held global medical technology company and leader in dialysis products based in Lund, Sweden. The transaction further enhances Baxter's global renal leadership and provides the company with a comprehensive product and therapies portfolio to meet the needs of patients in the large and growing dialysis market.

''The combination of these two respected renal leaders - Baxter and Gambro - will enable Baxter to better serve healthcare providers and patients through a collective offering of innovative renal products and therapies,'' said Robert L. Parkinson, Jr., chairman and chief executive officer of Baxter. ''Together, we will advance the state of dialysis care for patients with kidney disease worldwide.''

The acquisition provides a number of long-term growth opportunities for Baxter around the world. With a broad and complementary dialysis product portfolio and global footprint, Baxter can accelerate product sales in established markets such as Europe, where Gambro has an extensive presence. Baxter will also expand Gambro's reach in high-growth regions of Latin America and Asia-Pacific, where Baxter has steadily grown its peritoneal dialysis (PD) business. In addition, Baxter will build upon its core portfolio and pipeline of investigational home hemodialysis (HD) and automated PD systems by adding Gambro's dialyzers, devices and dialysis solutions, highly innovative and next-generation monitors, and acute therapies to treat patients with serious kidney, liver and lung conditions.

Brik Eyre has been named president of the combined Renal business and has been elected a corporate officer of Baxter by the company's Board of Directors. In his role, he will report to Robert M. Davis, president of Baxter's Medical Products business. Eyre joined Baxter in 2008 and previously served as the general manager of U.S. Medication Delivery. Prior to this role, Eyre served as general manager for Baxter's BioPharma Solutions business.

The total cash consideration for the transaction was approximately $3.9 billion USD. The transaction was financed through a combination of cash generated from overseas operations and debt issuances. The impact of the acquisition was included in Baxter's third quarter and full-year 2013 guidance.

Source:

Baxter International Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Baxter International Inc.. (2019, June 18). Combination of Baxter and Gambro enable Baxter to better serve innovative renal products and therapies. News-Medical. Retrieved on February 03, 2023 from https://www.news-medical.net/news/20130907/Combination-of-Baxter-and-Gambro-enable-Baxter-to-better-serve-innovative-renal-products-and-therapies.aspx.

  • MLA

    Baxter International Inc.. "Combination of Baxter and Gambro enable Baxter to better serve innovative renal products and therapies". News-Medical. 03 February 2023. <https://www.news-medical.net/news/20130907/Combination-of-Baxter-and-Gambro-enable-Baxter-to-better-serve-innovative-renal-products-and-therapies.aspx>.

  • Chicago

    Baxter International Inc.. "Combination of Baxter and Gambro enable Baxter to better serve innovative renal products and therapies". News-Medical. https://www.news-medical.net/news/20130907/Combination-of-Baxter-and-Gambro-enable-Baxter-to-better-serve-innovative-renal-products-and-therapies.aspx. (accessed February 03, 2023).

  • Harvard

    Baxter International Inc.. 2019. Combination of Baxter and Gambro enable Baxter to better serve innovative renal products and therapies. News-Medical, viewed 03 February 2023, https://www.news-medical.net/news/20130907/Combination-of-Baxter-and-Gambro-enable-Baxter-to-better-serve-innovative-renal-products-and-therapies.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post
You might also like...
Baxter seeks FDA approval of BAX 855 for treatment of people with hemophilia A